An open-label, single-dose, randomized, 4-period, crossover, bioequivalence study of 3 new formulations of Premarin /MPA 0.625 mg/2.5 mg compared with reference formulation of Premarin/MPA in healthy postmenopausal women.

Trial Profile

An open-label, single-dose, randomized, 4-period, crossover, bioequivalence study of 3 new formulations of Premarin /MPA 0.625 mg/2.5 mg compared with reference formulation of Premarin/MPA in healthy postmenopausal women.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2009

At a glance

  • Drugs Conjugated estrogens/medroxyprogesterone (Primary)
  • Indications Menopausal syndrome
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 03 Feb 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top